Decreased Acetylation of Histone H3 in Renal Cell Carcinoma: A Potential Target of Histone Deacetylase Inhibitors

Kent Kanao, Shuji Mikami, Ryuichi Mizuno, Toshiaki Shinojima, Masaru Murai, Mototsugu Oya

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: Recent studies suggest that alterations in chromatin structure by histone acetylation may have an important role in the neoplastic process. We evaluated histone H3 acetylation in renal cell carcinoma and the effects of a histone deacetylase inhibitor on renal cancer cell lines. Materials and Methods: The expression of acetylated histone H3 (Lys9) in renal cell carcinoma and corresponding nonneoplastic tissue specimens was evaluated. We next assessed immunohistologically the relationships between acetylated histone H3 expression and clinicopathological parameters in 44 cases of renal cell carcinoma. Furthermore, we evaluated the effects of the histone deacetylase inhibitor depsipeptide on the renal cancer cell lines Caki-1, ACHN, 769P and 786O (ATCC®). Results: Acetylated histone H3 expression was decreased in 85.0% of renal cell carcinomas compared to levels in nonneoplastic tissue. Decreased expression was related to high nuclear tumor grade and advanced pathological tumor stage (p = 0.048 and 0.032, respectively). Depsipeptide inhibited cell line proliferation in a time and dose dependent manner. Depsipeptide induced apoptosis in Caki-1, ACHN and 786O, and induced G2 cell cycle arrest in 769P. Concomitantly depsipeptide increased acetylated histone H3 and p21WAF/CIP1 expression, and induced Bcl-2 phosphorylation. Conclusions: These results suggest that the decreased acetylation of histone H3 is a common alteration in a malignant phenotype of renal cell carcinoma. Increasing the amount of acetylated histone H3 might be a therapeutic option for renal cell carcinoma.

Original languageEnglish
Pages (from-to)1131-1136
Number of pages6
JournalJournal of Urology
Volume180
Issue number3
DOIs
Publication statusPublished - 2008 Sep

Fingerprint

Histone Deacetylase Inhibitors
Acetylation
Renal Cell Carcinoma
Histones
Depsipeptides
Kidney Neoplasms
Cell Line
G2 Phase Cell Cycle Checkpoints
Neoplastic Processes
Chromatin
Neoplasms
Phosphorylation
Cell Proliferation
Apoptosis
Phenotype

Keywords

  • acetylation
  • carcinoma
  • gene expression
  • histones
  • kidney
  • renal cell

ASJC Scopus subject areas

  • Urology

Cite this

Decreased Acetylation of Histone H3 in Renal Cell Carcinoma : A Potential Target of Histone Deacetylase Inhibitors. / Kanao, Kent; Mikami, Shuji; Mizuno, Ryuichi; Shinojima, Toshiaki; Murai, Masaru; Oya, Mototsugu.

In: Journal of Urology, Vol. 180, No. 3, 09.2008, p. 1131-1136.

Research output: Contribution to journalArticle

@article{7457b90bc8894939be42e7395baf03f3,
title = "Decreased Acetylation of Histone H3 in Renal Cell Carcinoma: A Potential Target of Histone Deacetylase Inhibitors",
abstract = "Purpose: Recent studies suggest that alterations in chromatin structure by histone acetylation may have an important role in the neoplastic process. We evaluated histone H3 acetylation in renal cell carcinoma and the effects of a histone deacetylase inhibitor on renal cancer cell lines. Materials and Methods: The expression of acetylated histone H3 (Lys9) in renal cell carcinoma and corresponding nonneoplastic tissue specimens was evaluated. We next assessed immunohistologically the relationships between acetylated histone H3 expression and clinicopathological parameters in 44 cases of renal cell carcinoma. Furthermore, we evaluated the effects of the histone deacetylase inhibitor depsipeptide on the renal cancer cell lines Caki-1, ACHN, 769P and 786O (ATCC{\circledR}). Results: Acetylated histone H3 expression was decreased in 85.0{\%} of renal cell carcinomas compared to levels in nonneoplastic tissue. Decreased expression was related to high nuclear tumor grade and advanced pathological tumor stage (p = 0.048 and 0.032, respectively). Depsipeptide inhibited cell line proliferation in a time and dose dependent manner. Depsipeptide induced apoptosis in Caki-1, ACHN and 786O, and induced G2 cell cycle arrest in 769P. Concomitantly depsipeptide increased acetylated histone H3 and p21WAF/CIP1 expression, and induced Bcl-2 phosphorylation. Conclusions: These results suggest that the decreased acetylation of histone H3 is a common alteration in a malignant phenotype of renal cell carcinoma. Increasing the amount of acetylated histone H3 might be a therapeutic option for renal cell carcinoma.",
keywords = "acetylation, carcinoma, gene expression, histones, kidney, renal cell",
author = "Kent Kanao and Shuji Mikami and Ryuichi Mizuno and Toshiaki Shinojima and Masaru Murai and Mototsugu Oya",
year = "2008",
month = "9",
doi = "10.1016/j.juro.2008.04.136",
language = "English",
volume = "180",
pages = "1131--1136",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Decreased Acetylation of Histone H3 in Renal Cell Carcinoma

T2 - A Potential Target of Histone Deacetylase Inhibitors

AU - Kanao, Kent

AU - Mikami, Shuji

AU - Mizuno, Ryuichi

AU - Shinojima, Toshiaki

AU - Murai, Masaru

AU - Oya, Mototsugu

PY - 2008/9

Y1 - 2008/9

N2 - Purpose: Recent studies suggest that alterations in chromatin structure by histone acetylation may have an important role in the neoplastic process. We evaluated histone H3 acetylation in renal cell carcinoma and the effects of a histone deacetylase inhibitor on renal cancer cell lines. Materials and Methods: The expression of acetylated histone H3 (Lys9) in renal cell carcinoma and corresponding nonneoplastic tissue specimens was evaluated. We next assessed immunohistologically the relationships between acetylated histone H3 expression and clinicopathological parameters in 44 cases of renal cell carcinoma. Furthermore, we evaluated the effects of the histone deacetylase inhibitor depsipeptide on the renal cancer cell lines Caki-1, ACHN, 769P and 786O (ATCC®). Results: Acetylated histone H3 expression was decreased in 85.0% of renal cell carcinomas compared to levels in nonneoplastic tissue. Decreased expression was related to high nuclear tumor grade and advanced pathological tumor stage (p = 0.048 and 0.032, respectively). Depsipeptide inhibited cell line proliferation in a time and dose dependent manner. Depsipeptide induced apoptosis in Caki-1, ACHN and 786O, and induced G2 cell cycle arrest in 769P. Concomitantly depsipeptide increased acetylated histone H3 and p21WAF/CIP1 expression, and induced Bcl-2 phosphorylation. Conclusions: These results suggest that the decreased acetylation of histone H3 is a common alteration in a malignant phenotype of renal cell carcinoma. Increasing the amount of acetylated histone H3 might be a therapeutic option for renal cell carcinoma.

AB - Purpose: Recent studies suggest that alterations in chromatin structure by histone acetylation may have an important role in the neoplastic process. We evaluated histone H3 acetylation in renal cell carcinoma and the effects of a histone deacetylase inhibitor on renal cancer cell lines. Materials and Methods: The expression of acetylated histone H3 (Lys9) in renal cell carcinoma and corresponding nonneoplastic tissue specimens was evaluated. We next assessed immunohistologically the relationships between acetylated histone H3 expression and clinicopathological parameters in 44 cases of renal cell carcinoma. Furthermore, we evaluated the effects of the histone deacetylase inhibitor depsipeptide on the renal cancer cell lines Caki-1, ACHN, 769P and 786O (ATCC®). Results: Acetylated histone H3 expression was decreased in 85.0% of renal cell carcinomas compared to levels in nonneoplastic tissue. Decreased expression was related to high nuclear tumor grade and advanced pathological tumor stage (p = 0.048 and 0.032, respectively). Depsipeptide inhibited cell line proliferation in a time and dose dependent manner. Depsipeptide induced apoptosis in Caki-1, ACHN and 786O, and induced G2 cell cycle arrest in 769P. Concomitantly depsipeptide increased acetylated histone H3 and p21WAF/CIP1 expression, and induced Bcl-2 phosphorylation. Conclusions: These results suggest that the decreased acetylation of histone H3 is a common alteration in a malignant phenotype of renal cell carcinoma. Increasing the amount of acetylated histone H3 might be a therapeutic option for renal cell carcinoma.

KW - acetylation

KW - carcinoma

KW - gene expression

KW - histones

KW - kidney

KW - renal cell

UR - http://www.scopus.com/inward/record.url?scp=48649093238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48649093238&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.04.136

DO - 10.1016/j.juro.2008.04.136

M3 - Article

C2 - 18639283

AN - SCOPUS:48649093238

VL - 180

SP - 1131

EP - 1136

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -